SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Barings BDC (BBDC) Rating Upgrade to Buy

Barings BDC (BBDC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is the Options Market Predicting a Spike in Barings BDC Stock?

Investors need to pay close attention to BBDC stock based on the movements in the options market lately. 

Barings BDC, Inc. Announces Conference Call to Discuss Third Quarter 2026 Results

Barings BDC, Inc. (NYSE: BBDC) (Barings BDC or the Company) announced today that it will report its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, after the market closes. Barings BDC, Inc. has scheduled a conference call to discuss its third...

Barings BDC Q2 2026 Earnings Call Transcript

Barings BDC (NYSE:BBDC) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-time access toread more...

Notable Two Hundred Day Moving Average Cross - BBDC

In trading on Friday, shares of Barings BDC Inc (Symbol: BBDC) crossed below their 200 day moving average of $8.75, changing hands as low as $8.71 per share. Barings BDC Inc shares are currently trading down about 2.5% on the day. The chart below shows the one year performance...

Investors need to pay close attention to BBDC stock based on the movements in the options market lately.

Should Value Investors Buy Barings BDC (BBDC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Barings BDC (BBDC) Beats Q2 Earnings and Revenue Estimates

Barings BDC (BBDC) delivered earnings and revenue surprises of +12.00% and +6.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Barings BDC, Inc. Reports Second Quarter 2026 Results and Announces Quarterly Cash Dividend of $0.26 Per Share

Barings BDC, Inc. (NYSE: BBDC) (Barings BDC or the Company) today reported its financial and operating results for the second quarter of 2026 and announced that the Companys Board of Directors (the Board) declared a quarterly cash dividend of $0.26 per share. Highlights Three Months Ended Three...

Barings BDC, Inc. Announces Conference Call to Discuss Second Quarter 2026 Results

Barings BDC, Inc. (NYSE: BBDC) (Barings BDC or the Company) announced today that it will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, after the market closes. Barings BDC, Inc. has scheduled a conference call to discuss its second quarter...

Barings BDC, Inc., is an externally managed, closed-end management investment company that has been elected to be regulated as a business development company. It acts as co-investor and takes a minority interest. The company is headquartered in Charlotte, NC.

Barings BDC Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$8.65
Prev Close	$8.71
Open	$8.74
Dividend Yield	11.33%
50-Day Moving Average	$8.76
Beta	0.61
Avg. Volume	577,470.17
PE Ratio	10.49

52-Week High	$9.54
52-Week Low	$7.96
Market Capitalization	$912M
EPS (Annual)	$0.9688
Price to Book	0.80
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBDC Fundamentals